Tonix Pharmaceuticals Holding Revenue Growth Rates (TNXP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Tonix Pharmaceuticals Holding Corp   (NASDAQ: TNXP)
 

TNXP's Revenue Growth by Quarter and Year

Tonix Pharmaceuticals Holding 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TNXP/growth
https://api.csimarket.com/api/v1/companies/TNXP/fundamentals
https://api.csimarket.com/api/v1/companies/TNXP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TNXP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 17.23
2nd Quarter June 13.54
1st Quarter March 6.88
FY 37.65





TNXP Revenue third quarter 2026 Y/Y Growth Comment
Tonix Pharmaceuticals Holding Corp achieved in the third quarter 2026, above Company average Revenue surge of 423.83% year on year, to $ 17.23 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Tonix Pharmaceuticals Holding Corp ' s Revenue doubling of 423.83% ranks overall at the positon no. 74 in the third quarter 2026.


TNXP Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 423.83 %
2nd Quarter June 577 %
1st Quarter March 183.13 %
FY   -

Financial Statements
Tonix Pharmaceuticals Holding 's third quarter 2026 Revenue $ 17.23 millions TNXP's Income Statement
Tonix Pharmaceuticals Holding 's third quarter 2025 Revenue $ 3.29 millions Quarterly TNXP's Income Statement


TNXP Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 27.28 %
2nd Quarter June 96.8 %
1st Quarter March 27.64 %
FY (Year on Year)   -


Back to TNXP Growth rate Comparisons >> Back to TNXP Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #25
Overall #74

Revenue Y/Y Growth Statistics
High Average Low
577.88 % 101.72 % -31.68 %
(Jun 30 2026)   (Jun 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #25
Overall #74
Revenue Y/Y Growth Statistics
High Average Low
577.88 % 101.72 % -31.68 %
(Jun 30 2026)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Tonix Pharmaceuticals Holding 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
96.92 % 18 % -34.32 %
(Jun 30 2026)  


TNXP's III. Quarter Q/Q Revenue Comment
Tonix Pharmaceuticals Holding Corp achieved in the III. Quarter 2026 above company average sequential Revenue jump of 27.28%, to $ 17.23 millions, from $13.54 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Tonix Pharmaceuticals Holding 's Revenue growth quarter on quarter, overall rank is 131.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #45
Overall #131
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #45
Overall #131
Revenue Q/Q Growth Statistics
High Average Low
96.92 % 18 % -34.32 %
(Jun 30 2026)  


TNXP's III. Quarter Q/Q Revenue Comment
Tonix Pharmaceuticals Holding Corp achieved in the III. Quarter 2026 above company average sequential Revenue jump of 27.28%, to $ 17.23 millions, from $13.54 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Tonix Pharmaceuticals Holding 's Revenue growth quarter on quarter, overall rank is 131.


Tonix Pharmaceuticals Holding 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 29.10
Y / Y Revenue Growth (TTM) 196.02 %
Year on Year Revenue Growth Overall Ranking # 3336
Seqeuential Revenue Change (TTM) 65.77 %
Seq. Revenue Growth (TTM) Overall Ranking # 2756


Cumulative Revenue growth Comment
With 196.02% annual Revenue growth, Tonix Pharmaceuticals Holding Corp would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 450 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2727 to 3336.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 125
Healthcare Sector # 451
Overall # 3336

Revenue TTM Y/Y Growth Statistics
High Average Low
196.02 %
 54.17 %
-21.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 125
Sector # 395
S&P 500 # 2756
Cumulative Revenue growth Comment
With 196.02% annual Revenue growth, Tonix Pharmaceuticals Holding Corp would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 450 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2727 to 3336.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 125
Healthcare Sector # 451
Overall # 3336

Revenue TTM Y/Y Growth Statistics
High Average Low
196.02 %
54.17 %
-21.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 125
Sector # 395
S&P 500 # 2756




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TNXP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abeona Therapeutics Inc 706.88%$ 706.878 millions
Brightspring Health Services Inc 588.43%$ 588.428 millions
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions


About Tonix Pharmaceuticals Holding Revenue Growth Rates (TNXP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Tonix Pharmaceuticals Holding Corp (CIK 1430306).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001999371-26-024873
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Tonix Pharmaceuticals Holding Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.